Results 251 to 260 of about 6,254,499 (310)

Thrombolytic proteins profiling: High‐throughput activity, selectivity, and resistance assays

open access: yesFEBS Open Bio, EarlyView.
We present optimized biochemical protocols for evaluating thrombolytic proteins, enabling rapid and robust screening of enzymatic activity, inhibition resistance, and fibrin affinity, stimulation, and selectivity. The outcome translates to key clinical indicators such as biological half‐life and bleeding risk. These assays streamline the development of
Martin Toul   +3 more
wiley   +1 more source

Molecular determinants of signal transduction in tropomyosin receptor kinases

open access: yesFEBS Open Bio, EarlyView.
Tropomyosin receptor kinases control critical neuronal functions, but how do the same receptors produce diverse cellular responses? This review explores the structural mechanisms behind Trk signaling diversity, focusing on allosteric modulation and ligand bias.
Giray Enkavi
wiley   +1 more source

Pharmaceutical governance system for costly drugs through human rights due diligence.

open access: yesBMJ
Lemmens T   +5 more
europepmc   +1 more source

Day/night variations of myeloid and lymphoid cell subsets in the murine inguinal lymph node

open access: yesFEBS Open Bio, EarlyView.
The circadian system is involved in the temporal regulation of the immune system. Our study reveals that two innate immune populations, NKT cells and neutrophils, predominate at the beginning of the day in healthy mice, highlighting how the time of day influences immune responses.
Paula M. Wagner   +6 more
wiley   +1 more source

PMH51 ADHERENCE OF ALZHEIMER PATIENTS TO ANTIDEMENTIA DRUGS

open access: bronze, 2007
Oliver Schwalbe   +2 more
openalex   +1 more source

ATG4B is required for mTORC1‐mediated anabolic activity and is associated with clinical outcomes in non‐small cell lung cancer

open access: yesFEBS Open Bio, EarlyView.
The relationship between anabolic and catabolic processes governing lung cancer cell growth is nuanced. We show that ATG4B, an autophagy regulator, is elevated in lung cancer and that high ATG4B is associated with worse patient outcomes. Targeting ATG4B in cells reduces growth, protein synthesis, and mTORC1 activity, demonstrating a new relationship ...
Patrick J. Ryan   +6 more
wiley   +1 more source

Home - About - Disclaimer - Privacy